Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Electrum Advances AMT Geophysical Survey Identifying Additional Drill Targets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary... see more

Recent & Breaking News (NDAQ:EXEL)

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Business Wire 10 days ago

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

Business Wire January 7, 2026

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

Business Wire January 6, 2026

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

Business Wire December 3, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 16, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 15, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 13, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 12, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 10, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 9, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 8, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 7, 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

Business Wire November 6, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 6, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 5, 2025

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Business Wire November 4, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 4, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

ACCESS Newswire November 3, 2025

Podcasts